Abstract
The purpose of this review article is to examine the various studies that have evaluated microspheres for delivery of antimycobacterial drugs. Some of the studies strictly involve the development and evaluation of microspheres for use in antimycobacterial drug delivery, whereas others actually use drug-loaded microspheres to treat mycobacterial infections in cell lines and small animals. Although there is a potential to use microspheres to treat a variety of mycobacterial infections, it appears that most of the studies so far have focused on the etiological agent of tuberculosis, Mycobacterium tuberculosis. As a result, the infectious studies presented here all entail the treatment of that mycobacterial agent. This review will address the following aspects that are important if microspheres are to be considered an acceptable therapeutic tool: 1) in vitro release characteristics, 2) delivery, release and efficacy in macrophages, 3) effectiveness in infected small animal models, 4) safe and combined use with other antimycobacterial agents, and 5) reduced toxicity. It is hoped that once all of these parameters are evaluated, a conclusion regarding the benefit of microsphere technology in the treatment of mycobacterial diseases can be reached.
Keywords: mycobacterial infections, tuberculosis, microparticles, microspheres
Current Pharmaceutical Design
Title: Microsphere Technology for Chemotherapy of Mycobacterial Infections
Volume: 10 Issue: 26
Author(s): William W. Barrow
Affiliation:
Keywords: mycobacterial infections, tuberculosis, microparticles, microspheres
Abstract: The purpose of this review article is to examine the various studies that have evaluated microspheres for delivery of antimycobacterial drugs. Some of the studies strictly involve the development and evaluation of microspheres for use in antimycobacterial drug delivery, whereas others actually use drug-loaded microspheres to treat mycobacterial infections in cell lines and small animals. Although there is a potential to use microspheres to treat a variety of mycobacterial infections, it appears that most of the studies so far have focused on the etiological agent of tuberculosis, Mycobacterium tuberculosis. As a result, the infectious studies presented here all entail the treatment of that mycobacterial agent. This review will address the following aspects that are important if microspheres are to be considered an acceptable therapeutic tool: 1) in vitro release characteristics, 2) delivery, release and efficacy in macrophages, 3) effectiveness in infected small animal models, 4) safe and combined use with other antimycobacterial agents, and 5) reduced toxicity. It is hoped that once all of these parameters are evaluated, a conclusion regarding the benefit of microsphere technology in the treatment of mycobacterial diseases can be reached.
Export Options
About this article
Cite this article as:
Barrow W. William, Microsphere Technology for Chemotherapy of Mycobacterial Infections, Current Pharmaceutical Design 2004; 10 (26) . https://dx.doi.org/10.2174/1381612043383197
DOI https://dx.doi.org/10.2174/1381612043383197 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antimicrobial Activities of 1-H-Benzimidazole-based Molecules
Current Topics in Medicinal Chemistry Tumor Necrosis Factor-a Blockade in Rheumatoid Arthritis: Responders Vs Non Responders
Medicinal Chemistry Reviews - Online (Discontinued) Computer-Aided Design of a Novel Poly-Epitope Protein in Fusion with an Adjuvant as a Vaccine Candidate Against Leptospirosis
Current Proteomics Pulmonary Surfactant Proteins A and D: Innate Immune Functions and Biomarkers for Lung Diseases
Current Pharmaceutical Design Mechanism of Conjugated Imine and Iminium Species, including Marine Alkaloids: Electron Transfer, Reactive Oxygen Species, Therapeutics and Toxicity
Current Bioactive Compounds Bergenin - A Biologically Active Scaffold: Nanotechnological Perspectives
Current Topics in Medicinal Chemistry Synthesis, Stereochemical Studies and Antimycobacterial Activity of New Acetyl- Hydrazine Pyridazinones
Current Organic Synthesis A Review of the English and Russian Language Literature on the Osteoarticular Manifestations of Brucellosis Infection
Current Rheumatology Reviews Co-Crystals for Generic Pharmaceuticals: An Outlook on Solid Oral Dosage Formulations
Recent Advances in Drug Delivery and Formulation Synthesis and Antimycobacterial Activity of Highly Functionalised Pyrrolothiazole Derivatives
Letters in Drug Design & Discovery Orchestration of Host-Pathogen Interaction: Relevance of Iron in Generation of Potent Anti-M. tuberculosis Immunity
Current Pharmaceutical Biotechnology Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Editorial (Thematic Issue: Techniques and Application in Metabolomics: From Metabolite Profiling to Spatial Distribution)
Current Metabolomics Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry MIANN Models in Medicinal, Physical and Organic Chemistry
Current Topics in Medicinal Chemistry Old Drugs and New Targets as an Outlook for the Treatment of Tuberculosis
Current Medicinal Chemistry Antimalarial Drugs and their Useful Therapeutic Lives: Rational Drug Design Lessons from Pleiotropic Action of Quinolines and Artemisinins
Current Drug Discovery Technologies NAD Biosynthesis in Humans - Enzymes, Metabolites and Therapeutic Aspects
Current Topics in Medicinal Chemistry Anti-Oxidative Stress and Beyond: Multiple Functions of the Protein Glutathionylation
Protein & Peptide Letters Increased Expression of Forkhead Box Protein 3 Gene of Regulatory T Cells in Patients with Active Tuberculosis
Inflammation & Allergy - Drug Targets (Discontinued)